Indivior push to diversify boosted by schizophrenia drug approval

Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna. ... It will launch in competition to other monthly therapies, such as Lundbeck/Otsuka’s market leading Abilify Maintena (aripiprazole) and Johnson

First digital medicine approved in the US

The antipsychotic drug has a built-in digital tracking sensor. The FDA has approved Otsuka and Proteus Health’s Abilify MyCite, a pill with an embedded sensor that monitors whether patients ... Abilify MyCite is the latest iteration of antipsychotic

Lundbeck and Otsuka start phase III for Rexulti in bipolar

off the patent cliff in recent years and seen steep sales decline as a result, although a long-acting depot formulation (Abilify Maintena) is still making gains. ... Abilify. Lundbeck and Otsuka are also evaluating the drug in a phase II trial involving

Otsuka refiles 'digital' medicine for mental illness

Soluble sensor tracks drug ingestion and shares information with HCPs. Just over a year ago the FDA refused to approve the combination of Otsuka's Abilify with an ingestible sensor capsule ... The so-called 'digital medicine' consists of Otsuka's Abilify

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]